1. Home
  2. UCAR vs LYRA Comparison

UCAR vs LYRA Comparison

Compare UCAR & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo U Power Limited

UCAR

U Power Limited

HOLD

Current Price

$1.49

Market Cap

7.0M

ML Signal

HOLD

Logo Lyra Therapeutics Inc.

LYRA

Lyra Therapeutics Inc.

HOLD

Current Price

$1.44

Market Cap

5.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UCAR
LYRA
Founded
2013
2005
Country
China
United States
Employees
N/A
N/A
Industry
Retail-Auto Dealers and Gas Stations
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.0M
5.6M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
UCAR
LYRA
Price
$1.49
$1.44
Analyst Decision
Strong Buy
Hold
Analyst Count
1
1
Target Price
$5.00
$16.00
AVG Volume (30 Days)
39.9K
43.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,534,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.13
$0.08
52 Week High
$4.98
$37.50

Technical Indicators

Market Signals
Indicator
UCAR
LYRA
Relative Strength Index (RSI) 51.36 34.39
Support Level $1.44 $1.21
Resistance Level $2.17 $2.58
Average True Range (ATR) 0.12 0.15
MACD 0.02 0.05
Stochastic Oscillator 79.89 25.29

Price Performance

Historical Comparison
UCAR
LYRA

About UCAR U Power Limited

U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Share on Social Networks: